KPRX earnings analysis
What we found in KPRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Kiora Pharmaceuticals reported a notable decline in financial performance for Q4 2026 compared to the prior year, with a loss of $2.42M and zero revenue, leading to a significant miss on EPS expectations. The company continues to develop KIO-301 and KIO-104 while seeking further financing to maintain operations into late 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Zero Revenue Reported
- Kiora Pharmaceuticals reported $0.0 in revenue for Q4 2026, missing estimates of $1.5 million.
- EPS Miss
- The company reported an EPS of -1.6, significantly below the estimate of -0.54.
- Operating Expenses Increase
- Total operating expenses rose to $2.51 million, up from $2.33 million in Q4 2025.
- Cash Increased
- Total cash and cash equivalents rose to $11.0 million, compared to $8.7 million at year-end 2025.
- Private Placement Completed
- Kiora completed a private placement raising approximately $5.0 million in gross proceeds.
- Significant Clinical Pipeline
- The company is advancing multiple clinical trials, including KIO-301 and KIO-104 for ophthalmic diseases.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Losses
- Kiora has incurred cumulative losses of $156.6 million since inception and anticipates significant future losses.
- Financing Needs
- The company requires additional financing to support operations, with no committed sources of funds currently available.
- Regulatory Approval Risks
- Kiora may face challenges in gaining regulatory approval for its product candidates, which could impact future revenues.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.6
What they said about what is next.
The company anticipates having sufficient cash to fund operations into late 2028, contingent on successful financing.
The filing reads worse than the one before it.
What came before.
- 10-K · March 25, 2026
- Kiora is a clinical‑stage ophthalmology company advancing two Phase 2 programs: KIO-301 (ABACUS-2, a 36‑patient randomized trial in retinitis pigmentosa) and KIO-104 (KLARITY, Phase 2 enrollment and dosing began in 3Q…
- 10-Q · May 9, 2025
- Kiora reported Q1 (three months ended March 31, 2025) revenue of $0 and a net loss of $2,192,980 (GAAP EPS $(0.52)), compared with collaboration revenue of $16,000,000 and net income of $13,453,207 (EPS $4.67) in the…
- 10-Q · August 9, 2024
- Kiora reported Q2 FY2024 revenue of $20,000 and a quarterly net loss of $2,221,646 (basic EPS $(0.53)), a sharp sequential decline in revenue from the $16,000,000 collaboration recognized in Q1. Liquidity materially…
- 10-K · March 25, 2024
- Kiora is a clinical-stage ophthalmology company focused on photoswitch KIO-301 (RP/GA) and DHODH assets KIO-104/KIO-101 (uveitis/OPRA+) and KIO-201 (corneal wound healing). The 10‑K emphasizes a January 25, 2024…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KPRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever